BR112015031417A2 - forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem - Google Patents

forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem

Info

Publication number
BR112015031417A2
BR112015031417A2 BR112015031417A BR112015031417A BR112015031417A2 BR 112015031417 A2 BR112015031417 A2 BR 112015031417A2 BR 112015031417 A BR112015031417 A BR 112015031417A BR 112015031417 A BR112015031417 A BR 112015031417A BR 112015031417 A2 BR112015031417 A2 BR 112015031417A2
Authority
BR
Brazil
Prior art keywords
dosage form
cysteamine
pharmaceutical
methods
patient
Prior art date
Application number
BR112015031417A
Other languages
English (en)
Other versions
BR112015031417A8 (pt
BR112015031417B1 (pt
Inventor
Powell Kathlene
Muttavarapu Ramesh
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031417(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of BR112015031417A2 publication Critical patent/BR112015031417A2/pt
Publication of BR112015031417A8 publication Critical patent/BR112015031417A8/pt
Publication of BR112015031417B1 publication Critical patent/BR112015031417B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

1 / 1 resumo “forma de dosagem farmacãšutica, composiã‡ãƒo farmacãšutica, mã‰todos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem” a presente invenã§ã£o se refere a uma forma de dosagem de grã¢nulo com revestimento entã©rico de cisteamina e mã©todos relacionados de fabricaã§ã£o e uso.
BR112015031417-1A 2013-06-17 2014-06-17 Forma de dosagem farmacêutica BR112015031417B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17
US61/835,965 2013-06-17
PCT/US2014/042607 WO2014204881A1 (en) 2013-06-17 2014-06-17 Delayed release cysteamine bead formulation

Publications (3)

Publication Number Publication Date
BR112015031417A2 true BR112015031417A2 (pt) 2017-07-25
BR112015031417A8 BR112015031417A8 (pt) 2021-06-22
BR112015031417B1 BR112015031417B1 (pt) 2022-12-27

Family

ID=52019418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031417-1A BR112015031417B1 (pt) 2013-06-17 2014-06-17 Forma de dosagem farmacêutica

Country Status (25)

Country Link
US (9) US9233077B2 (pt)
EP (2) EP3010491A4 (pt)
JP (1) JP6468661B2 (pt)
KR (2) KR102466253B1 (pt)
CN (2) CN105492000B (pt)
AP (1) AP2015008925A0 (pt)
AR (1) AR096628A1 (pt)
AU (1) AU2014281702C1 (pt)
BR (1) BR112015031417B1 (pt)
CA (2) CA2938644C (pt)
CL (1) CL2015003662A1 (pt)
CU (1) CU20150178A7 (pt)
EA (1) EA031255B8 (pt)
HK (1) HK1218066A1 (pt)
IL (2) IL302141A (pt)
MX (1) MX2015017366A (pt)
NI (1) NI201500177A (pt)
NZ (1) NZ714517A (pt)
PH (1) PH12015502783A1 (pt)
SG (1) SG11201510126QA (pt)
TN (1) TN2015000549A1 (pt)
TW (1) TWI649100B (pt)
UA (1) UA117833C2 (pt)
WO (1) WO2014204881A1 (pt)
ZA (1) ZA201508783B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
WO2017087532A1 (en) * 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
WO2018093364A1 (en) * 2016-11-16 2018-05-24 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
WO2018170235A1 (en) * 2017-03-15 2018-09-20 Accera, Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CN1144585C (zh) 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
JP2005510537A (ja) 2001-11-29 2005-04-21 サウンド・ファーマシューティカルズ・インコーポレイテッド 化学療法の所望されない効果を改善する方法および組成物
CN1635882B (zh) 2002-01-04 2010-11-10 桑得医药品公司 组合物在制备治疗听力丧失的药物中的用途
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
AR047779A1 (es) 2003-12-19 2006-02-22 Omega Bio Pharma Ip3 Ltd Composiciones y metodos para tratar diabetes
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
EP1744737A2 (en) 2004-05-03 2007-01-24 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
CA2601339A1 (en) * 2005-03-29 2006-10-05 Roehm Gmbh Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance
ES2443653T3 (es) 2005-04-20 2014-02-20 Fred Hutchinson Cancer Research Center Procedimientos, composiciones y artículos de fabricación para mejorar la supervivencia de células, tejidos, órganos y organismos
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
CN104825430B (zh) 2007-11-30 2018-05-04 加利福尼亚大学董事会 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法
CN102006785A (zh) 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
CN102355893A (zh) * 2009-03-18 2012-02-15 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
WO2013078335A1 (en) * 2011-11-22 2013-05-30 The Regents Of The University Of California Cysteamine and/or cystamine for treating ischemic injury
TWI649100B (zh) 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法

Also Published As

Publication number Publication date
EA201690036A1 (ru) 2016-09-30
CA2938644C (en) 2019-08-27
US20140370085A1 (en) 2014-12-18
US11090279B2 (en) 2021-08-17
US20160158170A1 (en) 2016-06-09
KR20160045053A (ko) 2016-04-26
BR112015031417A8 (pt) 2021-06-22
AU2014281702C1 (en) 2020-05-14
JP2016523250A (ja) 2016-08-08
CA2914770C (en) 2016-09-27
UA117833C2 (uk) 2018-10-10
AR096628A1 (es) 2016-01-20
CA2914770A1 (en) 2014-12-24
US20190298665A1 (en) 2019-10-03
US9233077B2 (en) 2016-01-12
US20170319512A1 (en) 2017-11-09
EA031255B1 (ru) 2018-12-28
NZ714517A (en) 2018-10-26
AU2014281702B2 (en) 2019-11-07
AU2014281702A1 (en) 2015-12-10
SG11201510126QA (en) 2016-01-28
KR102466253B1 (ko) 2022-11-10
NI201500177A (es) 2016-02-15
EP3939574A1 (en) 2022-01-19
CU20150178A7 (es) 2016-07-29
AP2015008925A0 (en) 2015-12-31
CN110664780A (zh) 2020-01-10
WO2014204881A1 (en) 2014-12-24
ZA201508783B (en) 2019-09-25
TWI649100B (zh) 2019-02-01
US20170319514A1 (en) 2017-11-09
IL284823A (en) 2021-08-31
KR102281747B1 (ko) 2021-07-26
HK1218066A1 (zh) 2017-02-03
US9173851B1 (en) 2015-11-03
EA031255B8 (ru) 2019-11-29
TN2015000549A1 (en) 2017-04-06
KR20210094140A (ko) 2021-07-28
CL2015003662A1 (es) 2016-08-05
EP3010491A4 (en) 2016-05-18
WO2014204881A8 (en) 2016-02-18
TW201534357A (zh) 2015-09-16
US20170319513A1 (en) 2017-11-09
US20150290139A1 (en) 2015-10-15
CN105492000B (zh) 2019-11-15
CA2938644A1 (en) 2014-12-24
CN110664780B (zh) 2022-09-27
PH12015502783A1 (en) 2016-03-21
BR112015031417B1 (pt) 2022-12-27
CN105492000A (zh) 2016-04-13
EP3010491A1 (en) 2016-04-27
MX2015017366A (es) 2016-07-13
US20160095827A1 (en) 2016-04-07
IL302141A (en) 2023-06-01
JP6468661B2 (ja) 2019-02-13
US20160331704A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
EP3210604A4 (en) Uses of duloxetine hcl medicament in preparing pharmaceutical composition for treatment of cancer
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
MX2021001169A (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
IN2013MU03583A (pt)
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
EP3533451A4 (en) APPLICATION OF PAEENIFLORIN-6&#39;-O-BENZENE SULFONATE IN MEDICINE FOR THE TREATMENT OF SJÖGREN SYNDROME
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
GB2527233A (en) Composition comprising hydrocortisone
BR112015032161A2 (pt) método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica
EA201400444A1 (ru) Производные 2-оксопиперидинила

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HORIZON ORPHAN LLC (US)

B25G Requested change of headquarter approved

Owner name: HORIZON ORPHAN LLC (US)

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ;

Free format text: RETIFICACAO DO DESPACHO 25.1 ? TRANSFERENCIA DE TITULAR PUBLICADO NA RPI NO 2539, DE 03/09/2019, QUANTO AO ITEM 71 ? DEPOSITANTE, VISTO QUE TRATAVA-SE DE UMA TRANSFERENCIA PARCIAL.ONDE SE LE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIALEIA-SE: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA E HORIZON ORPHAN LLC.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2014, OBSERVADAS AS CONDICOES LEGAIS